1. In Vivo
  2. >>Market Intelligence

Transcatheter Systems Set To Dominate Heart Valve Market

 
• By Peter Charlish

Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.

Total worldwide sales of heart valve disease treatment systems are set to expand at a compound annual growth rate (CAGR) of 10.9%, increasing from approximately $4,8 billion in 2016 to an estimated $8.09 billion in 2021, according to "Heart Valve Repair and Replacement Devices Market", a June 2017 report from Informa's Meddevicetracker. Within that overall market, sales of heart valve disorder management products, which include percutaneous balloon valvuloplasty and surgical heart valve repair and replacement devices, will show a slight decline between now and 2021, while newer, less invasive and potentially safer techniques like transcatheter aortic valve replacement (TAVR) and mitral valve repair (TMVR) will continue to take market share.

Valvular heart disease occurs when there is inadequate opening or closing of an individual valve, sometimes accompanied by insufficiency or...

More from Market Intelligence

Tackling Fraud In The UK: Pharma, Are You Ready?

 
• By Trevor Francis

UK pharma faces a critical turning point as the Economic Crime and Corporate Transparency Act introduces the "Failure to Prevent Fraud" offense in September 2025, requiring companies to transform their approach to fraud prevention or face severe consequences.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.